Biovaxys Technology Corp
Canadian Securities Exchange:BIOVView on OTCQB

  • LAST PRICE
    0.0450
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    0.0400/ 186
  • Ask / Lots
    0.0450/ 35
  • Open / Previous Close
    0.0450 / 0.0450
  • Day Range
    0.0450
    0.0450
  • 52 Week Range
    0.0100
    0.1000
  • Volume
    440,730

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
BIOV
Biovaxys Technology Corp
11.5M
-1.5x
---
RKV
Rakovina Therapeutics Inc
9.9M
-2.6x
---
TELO
Telo Genomics Corp
9.7M
-3.0x
---
XRTX
XORTX Therapeutics Inc
6.1M
-3.1x
---
QNTM
Quantum BioPharma Ltd
11.6M
-0.3x
---
ASEP
Asep Medical Holdings Inc
7.4M
-1.3x
---
As of 2024-10-05

Company Information

BioVaxys Technology Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization and other immunological fields. The Company's clinical-stage pipeline includes maveropepimut-S, which is in phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its HapTenix neoantigen tumor cell construct platform for treating refractive late-stage ovarian cancer. The Company is also leveraging its expertise in tumor immunology by creating a unique library of T-lymphocytes and other datasets post-vaccination with its personalized immunotherapeutic vaccines to identify new targetable tumor antigens.

Contact Information

Headquarters
146 Thirtieth Street, Suite 100TORONTO, ON, Canada M8W 3D4
Phone
604-262-8835
Fax
604-262-8835

Executives

President, Chief Operating Officer
Kenneth Kovan
Chief Executive Officer, Director
James Passin
Director
Craig Loverock
Independent Director
Anthony Dutton

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$11.5M
Revenue (TTM)
$0.00
Shares Outstanding
256.0M
Biovaxys Technology Corp does not pay a dividend.
Beta
3.51
EPS
$-0.03
Book Value
$-0.02
P/E Ratio
-1.5x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.